title: Cardiac troponin I after external electrical cardioversion for atrial fibrillation as a marker of myocardial injury--a preliminary report.
abstract: BACKGROUND
  It is uncertain whether external electrical cardioversion (CV) of atrial fibrillation (AF) can cause myocardial injury identifiable by troponin I (cTnI).
  
  
  OBJECTIVE
  To examine whether external CV of AF can cause cTnI rise as measured with high-sensitivity assay, and to identify factors determining this elevation.
  
  
  METHODS
  Patients with non-valvular AF selected for CV were included. Exclusion criteria were myocardial ischaemia, elevated D-dimer, heart and renal failure. Patients underwent monophasic or biphasic CV. Troponin I was measured before, and 6 and 12 hours after the procedure with TNI-ADV assay; NT-proBNP was measured before CV. Echocardiography was performed in all patients.
  
  
  RESULTS
  Twenty-two patients were examined. Troponin I 6 and 12 hours after CV [0.04 ng/ml (0.00-0.30), 0.04 ng/ml (0.00-0.13)] was significantly higher than before [0.017 pg/ml (0.00-0.08)] (p=0.01, p=0.02). Only in one patient did cTnI exceed the cut-off for myocardial infarction after 6 hours (>0.16 ng/ml) with subsequent normalisation after 12 hours. Left ventricular end-diastolic dimension (LVEDD) was significantly higher and ejection fraction lower in the group with cTnI rise in comparison with the group with no cTnI elevation (54,2+/-6,3 vs. 47,6+/-5,7 mm, p=0,02; 56,2+/-8,9 vs. 63,2+/-7,1%, p=0,05). LVEDD=53 mm had 75% sensitivity and 72% specificity for predicting cTnI elevation after CV. Age, gender, AF duration, type of CV, energy, left atrial dimension, baseline cTnI and NT-proBNP were not predictive of cTnI increase.
  
  
  CONCLUSIONS
  Cardioversion can lead to mild but significant cTnI rise as measured with a high-sensitivity assay. The influence of CV on cTnI elevation appears to be more pronounced in patients with relatively large LVEDD.
authors.affiliation: Department of Internal Diseases and Cardiology, Military Medical Institute, ul. Szaserów 128, 00-909 Warsaw. wiktorpiechota@yahoo.pl
authors.forename: Wiktor
authors.initials: W
authors.lastname: Piechota
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Gielerak
authors.forename: Robert
authors.initials: R
authors.lastname: Ryczek
authors.forename: Anna
authors.initials: A
authors.lastname: Kaźmierczak
authors.forename: Jolanta
authors.initials: J
authors.lastname: Bejm
authors.forename: Wiesław
authors.initials: W
authors.lastname: Piechota
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000097:blood / Q000000981:diagnostic imaging / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D004452:Echocardiography; D004554:Electric Countershock / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D019210:Troponin I / Q000097:blood*
chemical_list: D015415:Biomarkers; D019210:Troponin I